Market Overview:
The Japan idiopathic pulmonary fibrosis treatment market size reached US$ 167.9 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 328.4 Million by 2032, exhibiting a growth rate (CAGR) of 7.74% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 167.9 Million |
Market Forecast in 2032
|
US$ 328.4 Million |
Market Growth Rate 2024-2032 |
7.74% |
Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial pneumonia characterized by the thickening and scarring of lung tissue. The clinical symptoms of IPF include breathing difficulties, persistent dry cough, fatigue, loss of appetite, and swollen limbs. It is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs, which slows the rate at which the scar tissues are formed and controls the symptoms associated with the disease. Supportive therapeutic options, including pulmonary rehabilitation, palliative care, and supplemental oxygen therapy, are also provided as the effective treatment plan for IPF.
Japan Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the IPF treatment market growth across Japan. This can be attributed to a rise in the consumption of nicotine-based products, a surge in pollution levels, and rising stress levels. Other than this, increasing health consciousness and rising awareness regarding the effective prevention and management strategies of IPF are acting as growth-inducing factors. Other factors, such as extensive research and development (R&D) activities for introducing novel therapies, and advancements in the existing healthcare infrastructure, are positively influencing the market growth across the country.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the Japan idiopathic pulmonary fibrosis treatment market report, along with forecasts at the country and regional levels from 2024-2032. Our report has categorized the market based on drug class and end user.
Breakup by Drug Class:
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
Breakup by End User:
- Hospitals
- Long-term Care Facilities
- Others
Breakup by Region:
- Kanto Region
- Kinki Region
- Central/ Chubu Region
- Kyushu-Okinawa Region
- Tohoku Region
- Chugoku Region
- Hokkaido Region
- Shikoku Region
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Million |
Segment Coverage |
Drug Class, End User, Region |
Region Covered |
Kanto Region, Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the Japan idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the Japan idiopathic pulmonary fibrosis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the Japan idiopathic pulmonary fibrosis treatment market and who are the key players?
- What is the degree of competition in the industry?